In conclusion, this study shows that canagliflozin treatment decreases the plasma concentration of TNFR1, IL-6, MMP7 and FN1 in individuals with type 2 diabetes and elevated albuminuria. This evidence concerns the gene IL6 and type 2 diabetes mellitus.